leisure time -WSS

leisure time

author：comprehensive 2025-10-01 14:17:31 - browse：3

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Will the FTC rein in IQVIA's health data empire?

WSS

Truvian presents data for its desktop blood

STAT Report: Patient voices and perspectives

6 phony surgeries that take placebo to the extreme

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

6 phony surgeries that take placebo to the extreme

The battle over 'scope creep' and who gets to be called 'doctor'

focus

leisure time

knowledge

Cancer drug shortages should be causing more outrage

Roche’s Alnylam deal shows drug firms interested in heart drugs

Medical leaders decry Supreme Court decision on affirmative action

Alabama hospital puts IVF treatments on hold

At least 13 dead in Texas as scorching temps continue

Alabama IVF ruling threatens families facing fatal genetic disease

Heart attack and stroke risk calculators need revising

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

United colonoscopy coverage change 'may cost lives,' doctors say

Biogen says it will cut costs by $700 million, slash 1,000 jobs

explore

Senate panel puts off hardest PBM reforms for another day

Dario to buy mental health app maker Twill in cash and stock deal

Former reverend arrested for allegedly killing 8

Democrats decry new health bill for going easy on private equity

STAT Report: Patient voices and perspectives

The battle over 'scope creep' and who gets to be called 'doctor'

explore

explore

hotspot

hotspot